Evaluation of the effect of high dose interalipid administration versus its gradual increase in neonates weighing less than 1500
Not Applicable
Completed
- Conditions
- advising of high doses interalipid.
- Registration Number
- IRCT20160120026115N6
- Lead Sponsor
- Vice chancellor for research of Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
All children born in Akbar Abadi Hospital with a birth weight of less than 1500 grams.
Had no perinatal asphyxia (Apgar 5 minutes below 6).
Parents had a written consent for entry into the study.
Had no major anomalies.
Exclusion Criteria
If there is any evidence of sepsis before randomization
If there is any evidence of metabolic acidosis before randomization
hypoxia less than 90% before randomization
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie high-dose interalipid effects in low-birth-weight neonates?
How does high-dose interalipid compare to standard lipid emulsion regimens in preterm infants?
Are there specific biomarkers that predict neonatal response to high-dose interalipid therapy?
What adverse events are associated with high-dose interalipid administration in neonates <1500g?
How do interalipid formulations compare to other lipid-based therapies for neonatal metabolic support?